PAYERS


Eli Lilly's diabetes drugs drive sales

Eli Lilly's diabetes drugs drive sales

The pharmaceutical company reported a 2% revenue increase in 2015, and diabetes medication is a key contributor.

Novartis says slow Entresto sales due to limited access

Novartis says slow Entresto sales due to limited access

In many cases, the drug required physicians to request prior authorization.

Five things for pharma marketers to know: Wednesday, December 16, 2015

Five things for pharma marketers to know: Wednesday, December 16, 2015

Britain says Bristol-Myers Squibb's Opdivo is too expensive; Calpers reports 32% boost in specialty drug spending; NIH is funding fewer clinical trials

Five things for pharma marketers to know: Friday, December 11, 2015

Five things for pharma marketers to know: Friday, December 11, 2015

UnitedHealth gives Praluent preferred status on its formularies; Stat News examines the first DTC drug ad; Britain to cover Entresto

Drugmakers explore response to pricing debate

Drugmakers explore response to pricing debate

Some pharma companies are taking steps to address concerns about the high prices of drugs at a time when Democratic lawmakers are urging price controls.

Five things for pharma marketers to know: Monday, November 9, 2015

Five things for pharma marketers to know: Monday, November 9, 2015

More patients may be eligible for new PCSK9 inhibitors; Collegium's painkiller may receive FDA approval; MannKind's Afrezza reports slow sales

Five things for pharma marketers to know: Friday, November 6, 2015

Five things for pharma marketers to know: Friday, November 6, 2015

Obama administration tells states they cannot restrict hep-C drugs; AstraZeneca says it will acquire ZS Pharma: Allergan CEO says drug discovery is too risky

Novartis: Cardiologists slow to advocate on behalf of new drugs

Novartis: Cardiologists slow to advocate on behalf of new drugs

The drugmaker said Entresto, its new heart-failure drug, brought in "modest sales" in the third quarter of 2015.

Turing price controversy fuels drug-pricing debate

Turing price controversy fuels drug-pricing debate

Attention turns to Valeant, which is facing subpoenas from two attorneys general who are seeking information about the drugmaker's patient-assistance, drug-pricing and drug-distribution practices.

Express Scripts to cover Repatha and Praluent

Express Scripts to cover Repatha and Praluent

The pharmacy benefit manager included both PCSK9 inhibitors on its national formulary. Spending on the drugs is estimated to reach $750 million in 2016.